EP3536689A1 - Dérivés de 2-(amine cyclique)éthylbenzamide en tant qu'inhibiteurs de p2x7 - Google Patents
Dérivés de 2-(amine cyclique)éthylbenzamide en tant qu'inhibiteurs de p2x7 Download PDFInfo
- Publication number
- EP3536689A1 EP3536689A1 EP19163637.2A EP19163637A EP3536689A1 EP 3536689 A1 EP3536689 A1 EP 3536689A1 EP 19163637 A EP19163637 A EP 19163637A EP 3536689 A1 EP3536689 A1 EP 3536689A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzamide
- ethyl
- chloro
- minutes
- lcms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CZOYBMCNBNGWFS-UHFFFAOYSA-N CCc1ncc(C(CNC(c(c(Cl)ccc2)c2Cl)=O)N(CC2)CCC2(F)F)cn1 Chemical compound CCc1ncc(C(CNC(c(c(Cl)ccc2)c2Cl)=O)N(CC2)CCC2(F)F)cn1 CZOYBMCNBNGWFS-UHFFFAOYSA-N 0.000 description 1
- SLYQLKHQLPKQKM-UHFFFAOYSA-N CN(C=C(C(CNC(c1cccc(Cl)c1Cl)=O)N(CC1)CCC1(F)F)C=C1)C1=O Chemical compound CN(C=C(C(CNC(c1cccc(Cl)c1Cl)=O)N(CC1)CCC1(F)F)C=C1)C1=O SLYQLKHQLPKQKM-UHFFFAOYSA-N 0.000 description 1
- LEBWXJZAWTVKFL-UHFFFAOYSA-N Cc(cc1)cc(C(O)=O)c1Cl Chemical compound Cc(cc1)cc(C(O)=O)c1Cl LEBWXJZAWTVKFL-UHFFFAOYSA-N 0.000 description 1
- WYPJOIBKVPORAF-UHFFFAOYSA-N Cc(cc1C(NCC(c2ccncc2)N2CCOCC2)=O)ccc1Cl Chemical compound Cc(cc1C(NCC(c2ccncc2)N2CCOCC2)=O)ccc1Cl WYPJOIBKVPORAF-UHFFFAOYSA-N 0.000 description 1
- TUONFDULYFJAFY-UHFFFAOYSA-N Cc(cc1C(NCC(c2ncccc2)N2CCOCC2)=O)ccc1Cl Chemical compound Cc(cc1C(NCC(c2ncccc2)N2CCOCC2)=O)ccc1Cl TUONFDULYFJAFY-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1ccc(C(C*C(c(cc(C)cc2)c2N)=O)*2CCOCC2)cc1 Chemical compound Cc1ccc(C(C*C(c(cc(C)cc2)c2N)=O)*2CCOCC2)cc1 0.000 description 1
- KJBSWXNPIPSJTL-UHFFFAOYSA-N Cc1ccccc1C(NCC(c(cc1)ccc1F)N1CCOCC1)=O Chemical compound Cc1ccccc1C(NCC(c(cc1)ccc1F)N1CCOCC1)=O KJBSWXNPIPSJTL-UHFFFAOYSA-N 0.000 description 1
- RTKBRHLMKAHOFE-UHFFFAOYSA-N Cc1ccccc1C(NCC(c(cc1)ccc1OC)N1CCOCC1)=O Chemical compound Cc1ccccc1C(NCC(c(cc1)ccc1OC)N1CCOCC1)=O RTKBRHLMKAHOFE-UHFFFAOYSA-N 0.000 description 1
- KPTGZRDOBIPGNV-UHFFFAOYSA-N Cc1ncc(C(CNC(c(c(Cl)ccc2)c2Cl)=O)N2CCOCC2)cn1 Chemical compound Cc1ncc(C(CNC(c(c(Cl)ccc2)c2Cl)=O)N2CCOCC2)cn1 KPTGZRDOBIPGNV-UHFFFAOYSA-N 0.000 description 1
- CJIGDZQDCYHUNP-UHFFFAOYSA-N Cc1ncc(C(CNC(c(cccc2F)c2Cl)=O)N2CCOCCC2)cn1 Chemical compound Cc1ncc(C(CNC(c(cccc2F)c2Cl)=O)N2CCOCCC2)cn1 CJIGDZQDCYHUNP-UHFFFAOYSA-N 0.000 description 1
- ASIZFIUHPKPOPQ-UHFFFAOYSA-N Cc1ncc(C(CNC(c2cc(F)cc(Cl)c2Cl)=O)N(CC2)CCC2(F)F)cn1 Chemical compound Cc1ncc(C(CNC(c2cc(F)cc(Cl)c2Cl)=O)N(CC2)CCC2(F)F)cn1 ASIZFIUHPKPOPQ-UHFFFAOYSA-N 0.000 description 1
- IXVNCKSUHHDFEP-UHFFFAOYSA-N Cc1ncc(C(CNC(c2cccc(Cl)c2Cl)=O)N(CC2)CCC2F)cn1 Chemical compound Cc1ncc(C(CNC(c2cccc(Cl)c2Cl)=O)N(CC2)CCC2F)cn1 IXVNCKSUHHDFEP-UHFFFAOYSA-N 0.000 description 1
- AXGMSNUKRWJXFR-OAHLLOKOSA-N Cc1ncc([C@@H](CNC(c(c(Cl)ccc2F)c2Cl)=O)N(CC2)CCC2(F)F)cn1 Chemical compound Cc1ncc([C@@H](CNC(c(c(Cl)ccc2F)c2Cl)=O)N(CC2)CCC2(F)F)cn1 AXGMSNUKRWJXFR-OAHLLOKOSA-N 0.000 description 1
- GIZNNAFXEWWKND-CQSZACIVSA-N Cc1ncc([C@@H](CNC(c(cccc2Cl)c2Cl)=O)N(CC2(F)F)CC2(F)F)cn1 Chemical compound Cc1ncc([C@@H](CNC(c(cccc2Cl)c2Cl)=O)N(CC2(F)F)CC2(F)F)cn1 GIZNNAFXEWWKND-CQSZACIVSA-N 0.000 description 1
- JLJUTXSVZMZSOR-UHFFFAOYSA-N N#Cc(cc1)cc(C(NCC(c(cc2)ccc2Cl)N2CCOCC2)=O)c1Cl Chemical compound N#Cc(cc1)cc(C(NCC(c(cc2)ccc2Cl)N2CCOCC2)=O)c1Cl JLJUTXSVZMZSOR-UHFFFAOYSA-N 0.000 description 1
- GNWXOVBWLWNRLH-UHFFFAOYSA-N NCC(c1ncccc1)N1CCOCC1 Chemical compound NCC(c1ncccc1)N1CCOCC1 GNWXOVBWLWNRLH-UHFFFAOYSA-N 0.000 description 1
- NZQPTKTVHYZJJL-UHFFFAOYSA-N O=C(c(c(Cl)ccc1)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F Chemical compound O=C(c(c(Cl)ccc1)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F NZQPTKTVHYZJJL-UHFFFAOYSA-N 0.000 description 1
- OMGUDCZSMVBUAI-UHFFFAOYSA-N O=C(c(cccc1)c1Cl)NCC(c1cnc(C(F)F)nc1)N(CC1)CCC1(F)F Chemical compound O=C(c(cccc1)c1Cl)NCC(c1cnc(C(F)F)nc1)N(CC1)CCC1(F)F OMGUDCZSMVBUAI-UHFFFAOYSA-N 0.000 description 1
- PISPNYWACGLJHN-UHFFFAOYSA-N O=C(c(cccc1Cl)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F Chemical compound O=C(c(cccc1Cl)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F PISPNYWACGLJHN-UHFFFAOYSA-N 0.000 description 1
- CKDQRIJGYPDNED-UHFFFAOYSA-N O=C(c(cccc1F)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F Chemical compound O=C(c(cccc1F)c1Cl)NCC(c1cnc(C(F)(F)F)nc1)N(CC1)CCC1(F)F CKDQRIJGYPDNED-UHFFFAOYSA-N 0.000 description 1
- YFJHJWYIIBVDPD-UHFFFAOYSA-N O=C(c(cccc1F)c1Cl)NCC(c1cnc(C(F)F)cc1)N(CC1)CCC1(F)F Chemical compound O=C(c(cccc1F)c1Cl)NCC(c1cnc(C(F)F)cc1)N(CC1)CCC1(F)F YFJHJWYIIBVDPD-UHFFFAOYSA-N 0.000 description 1
- JZLRFQTYCNCPGE-UHFFFAOYSA-N O=C(c1cccc(Cl)c1Cl)NCC(c1ccncc1)N1CCOCC1 Chemical compound O=C(c1cccc(Cl)c1Cl)NCC(c1ccncc1)N1CCOCC1 JZLRFQTYCNCPGE-UHFFFAOYSA-N 0.000 description 1
- UBUKDGULHSDGAK-UHFFFAOYSA-N O=C(c1cccc(Cl)c1Cl)NCC(c1cnccc1)N1CCOCC1 Chemical compound O=C(c1cccc(Cl)c1Cl)NCC(c1cnccc1)N1CCOCC1 UBUKDGULHSDGAK-UHFFFAOYSA-N 0.000 description 1
- FCTZSUCSZGLEKW-UHFFFAOYSA-N O=C(c1cccc(Cl)c1Cl)NCC(c1ncccc1)N1CCOCC1 Chemical compound O=C(c1cccc(Cl)c1Cl)NCC(c1ncccc1)N1CCOCC1 FCTZSUCSZGLEKW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention is directed to novel compounds which inhibit the P2X 7 receptor.
- Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat pain, inflammation, neurological disorders, or neuropsychiatric disorders.
- the purinergic 2X 7 (P2X 7 ) receptor is a ligand-gated ion channel which is activated by extracellular ATP and is present on a variety of cell types, including microglia in the central nervous system and other cells involved in inflammation and immune system function.
- the P2X 7 receptor has been shown to have a role in cytolysis in the immune system ( Surprenant, et al. Science, 272, 735-41, 1996 ), and is involved in activation of lymphocytes and monocyte/macrophages leading to the increased release of pro-inflammatory cytokines (e.g., TNF ⁇ and IL1 ⁇ ) from these cells ( Ferrari, et al. Neuropharmacol, 36, 1295-301, 1997 ).
- pro-inflammatory cytokines e.g., TNF ⁇ and IL1 ⁇
- P2X 7 receptor activation results in a therapeutic effect ( DiVirgilio, et al. Drug Dev Res, 45, 207-13, 1998 ).
- inflammation e.g., rheumatoid arthritis and other autoimmune diseases, osteoarthritis, asthma, chronic obstructive pulmonary disease and inflammatory bowel disease
- interstitial fibrosis results in a therapeutic effect
- P2X 7 receptor antagonists may find use in the treatment and prophylaxis of pain, including acute, chronic and neuropathic pain ( Chessel, et al, Pain, 114, 386-96, 2005 ).
- Inhibiting P2X 7 activation may also diminish or reduce cell death caused by prolongation of activated P2X 7 receptors, indicating a potential therapeutic intervention for said antagonists in nervous system injury or degeneration ( Sperlagh, et al., Progress in Neurobiology, 7, 327-346, 2006 ). Vianna, et al. (Epilepsia, 43, 27-229, 2002 ) also revealed a potential role for P2X 7 receptors in the pathogenesis of epilepsy.
- P2X 7 receptor antagonists are desirable as useful agents for therapeutic intervention in the central nervous system for treating pain, inflammation, neurological and neurodegenerative disorders, neuropsychiatric disorders, or other disorders for which the reduction or otherwise stabilization of pro-inflammatory cytokines is beneficial.
- the present invention fulfills this need, and provides further related advantages.
- An objective of the present invention is to provide compounds that inhibit P2X 7 receptors. Accordingly, the present invention relates to compounds of Formula I.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, excipient or diluent.
- the compounds of Formula I may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
- the compounds of Formula I may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers can be separated in a manner known to a person skilled in the art.
- the present invention further provides methods for treating pain or inflammation in a subject, comprising administering to a subject suffering from pain or inflammation a therapeutically effective amount of a compound of Formula I.
- the present invention further provides methods for treating an affective disorder in a subject comprising administering to a subject suffering from an affective disorder a therapeutically effective amount of at least one compound of Formula I.
- the present invention further provides methods for treating a neurological disorder or neurodegenerative disorder in a subject comprising administering to a subject suffering from a neurological disorder or neurodegenerative disorder a therapeutically effective amount of at least one compound of Formula I.
- the present invention further provides methods for treating depression, major depressive disorder, treatment resistant depression, anxiety, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), neuropathic pain, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, epilepsy, Parkinson's Disease, Huntington's Disease and Alzheimer's disease, which involves administering a compound of Formula I.
- the present invention also provides the use a compound of Formula I for the manufacture of a medicament for the treatment of affective disorders.
- the present invention also provides a compound of Formula I for use in treating an affective disorder in a subject.
- the present invention is based on the discovery of the compounds of Formula I, which are inhibitors of the P2X 7 receptor, and as such, are useful for the treatment of related disorders. Additionally, certain aspects of the invention are explained in greater detail below but this description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. Hence, the following specification is intended to illustrate some embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.
- R 1 is optionally substituted phenyl. In one embodiment, R 1 is optionally substituted pyridyl. In another embodiment, R 1 is optionally substituted pyrazinyl. In one embodiment, R 1 is optionally substituted pyrimidyl. In one embodiment, R 1 is optionally substituted 5 membered heteroaryl. In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted piperazinyl. In yet embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted piperidinyl. In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted morpholinyl.
- R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted pyrrolidinyl. In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted pyrrolo.
- R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted imidazo. In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted 6 to 10 membered spiro(heterocyclyl).
- R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted homomorpholinyl In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted homopiperidinyl In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted homopiperazinyl In one embodiment, R 2a and R 2b combine with the nitrogen to which they are attached to form optionally substituted azetidinyl.
- R 3 is chlorine, methyl or trifluorormethyl.
- n is 0. In one embodiment, n is 1. In one embodiment, n is 2.
- R 4 is fluorine, chlorine, C 1-3 alkyl, C 1-4 fluoroalkyl, cyano, C 1-3 alkoxy or C 1-4 fluoroalkoxy.
- C 1 -C 6 alkyl refers to a straight chained or branched saturated hydrocarbon having from one to six carbon atoms inclusive.
- substituents include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, n-pentyl and n-hexyl.
- straight chained or branched C 1 -C 3 alkyl refers to a saturated hydrocarbon having from one to three carbon atoms inclusive. Examples of such substituents include, but are not limited to, methyl, ethyl and n-propyl.
- C 1 -C 6 alkoxy refers to a straight chained or branched saturated alkoxy group having from one to six carbon atoms inclusive with the open valency on the oxygen.
- substituents include, but are not limited to, methoxy, ethoxy, n-butoxy, t-butoxy and n-hexyloxy.
- C 1 -C 4 fluoroalkyl refers to a straight chained or branched saturated hydrocarbon having from one to four carbon atoms inclusive substituted with one or more fluorine atoms.
- substituents include, but are not limited to, trifluoromethyl, pentafluoroethyl, 1-fluoroethyl, monofluoromethyl, difluoromethyl and 1,2-difluoroethyl.
- C 1 -C 4 fluoroalkoxy refers to a straight chained or branched saturated alkoxy group having from one to four carbon atoms inclusive with the open valency on the oxygen and in which one or more carbon atoms are substituted with one or more fluorine atoms.
- substituents include, but are not limited to, monofluoromethoxy, 1,1-difluoroethoxy and 1-monofluoro-n-butoxy.
- C 3-6 cycloalkyl refers to saturated monocyclic hydrocarbon groups. Examples of such systems include, but are not limited to, cyclopropyl, cyclobutyl or cyclohexyl
- 5 membered heteroaryl refers to a fully unsaturated aromatic monocyclic ring system having 1-4 heteroatoms. Examples of such systems include, but are not limited to, thienyl, furyl, imidazolyl and pyrrolyl.
- 6 to 10 membered spiro(heterocyclyl) refers to a heterocyclic ring which is a fused bicyclic system.
- heterocyclic ring which is a fused bicyclic system.
- examples of such systems include, but are not limited to, 2-oxa-6-aza-spiro[3.3]heptane, 2-aza-spiro[3.3]heptane and 2,6-diaza-spiro[3.3]heptane.
- halogen refers to fluorine, chlorine, bromine and iodine.
- the phrase "effective amount” when applied to a compound of the invention is intended to denote an amount sufficient to cause an intended biological effect.
- the phrase "therapeutically effective amount” when applied to a compound of the invention is intended to denote an amount of the compound that is sufficient to ameliorate, palliate, stabilize, reverse, slow or delay the progression of a disorder or disease state, or of a symptom of the disorder or disease.
- the method of the present invention provides for administration of combinations of compounds. In such instances, the "effective amount” is the amount of the combination sufficient to cause the intended biological effect.
- treatment means ameliorating or reversing the progress or severity of a disease or disorder, or ameliorating or reversing one or more symptoms or side effects of such disease or disorder.
- Treatment or “treating”, as used herein, also means to inhibit or block, as in retard, arrest, restrain, impede or obstruct, the progress of a system, condition or state of a disease or disorder.
- treatment or “treating” further means an approach for obtaining beneficial or desired clinical results, where "beneficial or desired clinical results” include, without limitation, alleviation of a symptom, diminishment of the extent of a disorder or disease, stabilized (i.e., not worsening) disease or disorder state, delay or slowing of a disease or disorder state, amelioration or palliation of a disease or disorder state, and remission of a disease or disorder, whether partial or total, detectable or undetectable.
- the present invention also comprises salts of the present compounds, typically, pharmaceutically acceptable salts.
- Such salts include pharmaceutically acceptable acid addition salts.
- Acid addition salts include salts of inorganic acids as well as organic acids.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-tol
- the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
- Racemic forms may be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Separation of such diastereomeric salts can be achieved, e.g. by fractional crystallization.
- the optically active acids suitable for this purpose may include, but are not limited to d- or 1- tartaric, mandelic or camphorsulfonic acids. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix.
- the compounds of the present invention may also be resolved by the formation and chromatographic separation of diastereomeric derivatives from chiral derivatizing reagents, such as, chiral alkylating or acylating reagents, followed by cleavage of the chiral auxiliary. Any of the above methods may be applied either to resolve the optical antipodes of the compounds of the invention per se or to resolve the optical antipodes of synthetic intermediates, which can then be converted by methods described herein into the optically resolved final products which are the compounds of the invention.
- Optically active compounds can also be prepared from optically active starting materials.
- the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable carrier.
- the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the specific compounds disclosed in the Experimental Section and a pharmaceutically acceptable carrier.
- the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
- the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995 .
- compositions may be specifically formulated for administration by an oral route.
- Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
- Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
- inhibitor means to reduce, diminish, block or even eliminate, such as in e.g. "inhibiting P2X 7 receptor activity".
- Inhibiting P2X 7 receptor activity or “inhibiting P2X 7 activity” as used herein means, e.g. reducing or even eliminating the ability of a P2X 7 receptor to exhibit a cellular response, such as inhibiting the response to stimuli or agonist ligands, or inhibiting the production or accumulation of IL1 ⁇ .
- the present invention also provides a method of treating a disease or disorder, the method comprising administering a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof to a mammal suffering from (or at risk for) the disease or disorder, or otherwise in need of the treatment.
- the present invention also provides a method of treating pain or inflammation, the method comprising administering a therapeutically effective amount of at least one compound of the present invention or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
- the pain that may be treated using the compounds described herein, including acute, chronic or inflammatory pain is caused by neuropathic pain, post-operative pain, morphine tolerance, fibromyalgia, neuralgias, headache, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, irritable bowel syndrome or inflammatory bowel disease.
- the disease or disorder that may be treated using the compounds described herein is a neurological disorder or neurodegenerative disorder, such as epilepsy, multiple sclerosis, Parkinson's disease, Huntington's disease or Alzheimer's disease.
- the term "neurological disorder” means a disorder of the nervous system, and includes, but is not limited to, the disorders as described hereinabove. Based on the well-known meaning of disorders of the nervous system, neurological disorders result from structural, biochemical, electrical, or cellular (neuronal or microglial) signaling abnormalities that may occur in the brain or spinal cord of the afflicted mammal.
- neurodegenerative disorder means a disorder characterized by symmetrical and progressive loss of structure or function of neurons, such as death of neurons or reduced growth of neurons. Such loss of neurons may affect motor, sensory, or cognitive neuronal systems.
- treating a neurological or neurodegenerative disorder using the compounds described herein may result in the amelioration or relief of symptoms of the neurological or neurodegenerative disorder, such symptoms as paralysis, muscle weakness, poor coordination, uncontrolled movements, seizures, confusion, altered levels of consciousness, memory loss, emotional instability, loss of sensation, pain, and similar symptoms.
- the disease or disorder is a neuropsychiatric disorder, such as an affective disorder.
- an affective disorder means a mental disorder characterized by a consistent, pervasive alteration of mood, and affecting thoughts, emotions and behaviors.
- Affective disorders include mood disorders as described in DSM-IV-TR® ( American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) doi: 10.1176/appi.books.9780890423349 ; which is incorporated by reference herein).
- treating an affective disorder using the compounds described herein may result in the amelioration, stabilization or otherwise diminishment or relief of symptoms of the affective disorder, such symptoms as mood instability, manic episodes, feelings of guilt or worthlessness, sleep disturbances, agitation, or the like.
- affective disorders include, but are not limited to, depressive disorders, anxiety disorders, bipolar disorders, dysthymia and schizoaffective disorders.
- Anxiety disorders include, but are not limited to, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, phobias, and post-traumatic stress disorder (PTSD).
- Depressive disorders include, but are not limited to, major depressive disorder (MDD), catatonic depression, melancholic depression, atypical depression, psychotic depression, postpartum depression, treatment-resistant depression, bipolar depression, including bipolar I and bipolar II, and mild, moderate or severe depression.
- MDD major depressive disorder
- Catatonic depression melancholic depression
- melancholic depression atypical depression
- psychotic depression postpartum depression
- bipolar depression including bipolar I and bipolar II
- mild, moderate or severe depression include, but are not limited to, paranoia, antisocial and borderline personality disorders.
- the affective disorder treated using the compounds described herein is depression, major depressive disorder (MDD), treatment-resistant depression, bipolar disorder, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, or post-traumatic stress disorder (PTSD), or a combination thereof.
- MDD major depressive disorder
- bipolar disorder generalized anxiety disorder
- panic disorder panic disorder
- obsessive-compulsive disorder or post-traumatic stress disorder (PTSD)
- PTSD post-traumatic stress disorder
- the present invention provides a method of treating an affective disorder in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula I.
- the present invention provides a method of inhibiting P2X 7 activity in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formula I.
- the present invention also provides a method of inhibiting production or accumulation of IL1 ⁇ , comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula I.
- the present invention provides the use of a compound of Formula I for the manufacture of a medicament for the treatment of affective disorders.
- the present invention also provides the use of a compound of Formula I for the manufacture of a medicament for the inhibition of P2X 7 activity.
- the present invention further provides the use of a compound of Formula I for the manufacture of a medicament for the inhibition of production or accumulation of IL1 ⁇ .
- the present invention provides at least one compound of Formula I for use in treating an affective disorder in a subject. In an embodiment, the present invention provides at least one compound of Formula I for use in inhibiting P2X 7 activity in a subject. In an embodiment, the present invention provides at least one compound of Formula I for use in inhibiting production or accumulation of IL1 ⁇ in a subject.
- the invention also provides a compound of Formula I for use in therapy of a subject, for example, in the treatment of affective disorders.
- the schemes may involve the use of selective protecting groups during the synthesis of the compounds of the invention.
- One skilled in the art would be able to select the appropriate protecting group for a particular reaction. It may be necessary to incorporate protection and de-protection strategies for substituents such as amino, amido, carboxylic acid and hydroxyl groups in the synthetic methods described below to synthesize the compounds of Formula I. Methods for protection and de-protection of such groups are well known in the art, and may be found in T. Green, et al., Protective Groups in Organic Synthesis, 1991, 2nd Edition, John Wiley & Sons, New York .
- Benzoic acids of formula II are commercially available or available by methods described in the literature (see for example Shaikh, Tanveer Mahammad Ali, J.Org. Chem (2006), 71, 5043-5046 and Mongin, Florence; Tetrahedron Lett. (1996), 37, 6551-6554 ).
- PdOAc 2 22 mg, 0.1 mmol
- 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl 53 mg, 0,13 mmol
- cesium carbonate 880 mg, 2.70 mmol
- potassium trifluoro(vinyl)borate 145 mg, 1.1 mmol
- THF 10 ml
- water 3 ml
- 5-bromo-2-(1,1-difluoroethyl)pyrimidine 200 mg, 0,897 mmol
- This reaction is typically carried out in a solvent such as THF or DMF, employing peptide coupling reagents exemplified by, but not limited to EDC and HOBt in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine (DIPEA), at a temperature ranging from about 10° C to about 30° C.
- a tertiary amine base such as triethylamine or diisopropylethylamine (DIPEA)
- Other non-limiting examples of coupling reagents include carbonyldiimidazole, N,N'-dicyclohexylcarbodiimide or benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate as reported by Coste et al. Tetrahedron Lett. (1990) 31 (2): 205 .
- Compounds of formula I can be prepared by employing standard
- This reaction is typically carried out in a solvent such as THF, DCM or DMF in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine (DIPEA), at a temperature ranging from about 10° C to about 30° C.
- a solvent such as THF, DCM or DMF
- DIPEA diisopropylethylamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261713099P | 2012-10-12 | 2012-10-12 | |
PCT/EP2013/071253 WO2014057080A2 (fr) | 2012-10-12 | 2013-10-11 | Amines cycliques |
EP13786436.9A EP2906549B1 (fr) | 2012-10-12 | 2013-10-11 | Dérivés de n-(2-(amine cyclique)ethyl)benzamide en tant qu'inhibiteurs de p2x7 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13786436.9A Division EP2906549B1 (fr) | 2012-10-12 | 2013-10-11 | Dérivés de n-(2-(amine cyclique)ethyl)benzamide en tant qu'inhibiteurs de p2x7 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3536689A1 true EP3536689A1 (fr) | 2019-09-11 |
Family
ID=49546380
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13786436.9A Active EP2906549B1 (fr) | 2012-10-12 | 2013-10-11 | Dérivés de n-(2-(amine cyclique)ethyl)benzamide en tant qu'inhibiteurs de p2x7 |
EP19163637.2A Withdrawn EP3536689A1 (fr) | 2012-10-12 | 2013-10-11 | Dérivés de 2-(amine cyclique)éthylbenzamide en tant qu'inhibiteurs de p2x7 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13786436.9A Active EP2906549B1 (fr) | 2012-10-12 | 2013-10-11 | Dérivés de n-(2-(amine cyclique)ethyl)benzamide en tant qu'inhibiteurs de p2x7 |
Country Status (29)
Country | Link |
---|---|
US (6) | US9108938B2 (fr) |
EP (2) | EP2906549B1 (fr) |
JP (2) | JP6333827B2 (fr) |
KR (1) | KR20150067189A (fr) |
CN (1) | CN104955819B (fr) |
AP (1) | AP2015008407A0 (fr) |
AR (1) | AR092975A1 (fr) |
AU (1) | AU2013328586B2 (fr) |
BR (1) | BR112015008123A2 (fr) |
CA (1) | CA2886559A1 (fr) |
CL (1) | CL2015000879A1 (fr) |
CR (1) | CR20150184A (fr) |
DO (1) | DOP2015000078A (fr) |
EA (1) | EA201590669A1 (fr) |
EC (1) | ECSP15014177A (fr) |
HK (1) | HK1213880A1 (fr) |
IL (1) | IL238011A0 (fr) |
MA (1) | MA37989A1 (fr) |
MX (1) | MX2015004414A (fr) |
NI (1) | NI201500052A (fr) |
NZ (1) | NZ630816A (fr) |
PE (1) | PE20150638A1 (fr) |
PH (2) | PH12015500795B1 (fr) |
RU (1) | RU2015116112A (fr) |
SG (1) | SG11201502684YA (fr) |
TN (1) | TN2015000114A1 (fr) |
TW (1) | TW201427947A (fr) |
WO (1) | WO2014057080A2 (fr) |
ZA (1) | ZA201503246B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
EA029644B1 (ru) | 2012-12-12 | 2018-04-30 | Идорсиа Фармасьютиклз Лтд | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов |
EP2935211B1 (fr) | 2012-12-18 | 2016-11-09 | Actelion Pharmaceuticals Ltd. | Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 |
US9388197B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
ES2616883T3 (es) | 2013-01-22 | 2017-06-14 | Actelion Pharmaceuticals Ltd. | Derivados amida heterocíclicos como antagonistas del receptor P2X7 |
EP3962493A2 (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001046200A1 (fr) * | 1999-12-22 | 2001-06-28 | Astrazeneca Ab | Nouveaux derives de piperidine et de piperazine |
WO2009132000A1 (fr) * | 2008-04-22 | 2009-10-29 | Janssen Pharmaceutica Nv | Antagonistes de p2x7 substitués par une quinoline ou isoquinoline |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445707A1 (de) | 1962-05-05 | 1969-03-13 | Hoechst Ag | Piperidinverbindungen und Verfahren zu ihrer Herstellung |
US3435038A (en) | 1965-06-01 | 1969-03-25 | Sandoz Ag | 5,6,7,9,10,14b-hexahydroisoquinolo (2,1-d) benzo (1,4) diazepines |
US6194458B1 (en) | 1998-10-30 | 2001-02-27 | Merck & Co., Inc. | Benzamide potassium channel inhibitors |
US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
WO2003010132A1 (fr) | 2001-07-17 | 2003-02-06 | Akzo Nobel N.V. | Dérivés de n-[(1-diméthylaminocycloalkyl)méthyl]benzamide |
TW200300083A (en) | 2001-11-12 | 2003-05-16 | Pfizer Prod Inc | Benzamide, heteroarylamide and reverse amides |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
JP4731468B2 (ja) | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
EP1500651A1 (fr) | 2003-07-25 | 2005-01-26 | Bayer CropScience S.A. | Composés de N-[2-(2-pyridinyl)éthyl]benzamide et leur utilisation comme fongicides |
CA2539227A1 (fr) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
TWI368482B (en) | 2003-12-19 | 2012-07-21 | Bayer Sas | New 2-pyridinylethylbenzamide derivatives |
US7825135B2 (en) | 2004-03-24 | 2010-11-02 | Merck Sharp & Dohme Limited | Heteroaryl piperidine glycine transporter inhibitors |
EP1773776A1 (fr) | 2004-07-23 | 2007-04-18 | Bayer Cropscience Sa | Dérivés de 3-pyridylethylbenzamide comme fungicides |
US7655644B2 (en) | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
CA2611376C (fr) * | 2005-06-13 | 2013-09-10 | Merck Sharp & Dohme Limited | Agents therapeutiques |
ATE425138T1 (de) | 2005-10-19 | 2009-03-15 | Hoffmann La Roche | N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase |
JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
TWI435863B (zh) | 2006-03-20 | 2014-05-01 | Nihon Nohyaku Co Ltd | N-2-(雜)芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑 |
AR067381A1 (es) | 2007-07-02 | 2009-10-07 | Syngenta Participations Ag | Derivados amido y/o amino tiofenos con actividad microbicida,composiciones que los contienen y usos de las mismas para prevenir y/o controlar la infeccion de plantas por microorganismos patogenos,preferentemente hongos. |
ITMC20070152A1 (it) | 2007-07-26 | 2009-01-27 | Faggiolati Pumps Spa | Miscelatore sommerso in particolare miscelatore sommerso per vasche di trattamento delle acque reflue. |
WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
ES2345527B1 (es) | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
CA2804716A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Composes chimiques |
MX345339B (es) | 2011-03-02 | 2017-01-25 | Univ Tokyo | Agente de control de endoparásitos. |
JP2015501326A (ja) | 2011-11-02 | 2015-01-15 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 殺線虫活性を有する化合物 |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
-
2013
- 2013-10-09 TW TW102136495A patent/TW201427947A/zh unknown
- 2013-10-10 AR ARP130103684A patent/AR092975A1/es unknown
- 2013-10-10 US US14/050,466 patent/US9108938B2/en not_active Expired - Fee Related
- 2013-10-11 WO PCT/EP2013/071253 patent/WO2014057080A2/fr active Application Filing
- 2013-10-11 JP JP2015536144A patent/JP6333827B2/ja not_active Expired - Fee Related
- 2013-10-11 EP EP13786436.9A patent/EP2906549B1/fr active Active
- 2013-10-11 AP AP2015008407A patent/AP2015008407A0/xx unknown
- 2013-10-11 EP EP19163637.2A patent/EP3536689A1/fr not_active Withdrawn
- 2013-10-11 CA CA2886559A patent/CA2886559A1/fr not_active Abandoned
- 2013-10-11 CN CN201380053128.8A patent/CN104955819B/zh not_active Expired - Fee Related
- 2013-10-11 AU AU2013328586A patent/AU2013328586B2/en not_active Ceased
- 2013-10-11 EA EA201590669A patent/EA201590669A1/ru unknown
- 2013-10-11 MA MA37989A patent/MA37989A1/fr unknown
- 2013-10-11 NZ NZ630816A patent/NZ630816A/en not_active IP Right Cessation
- 2013-10-11 RU RU2015116112A patent/RU2015116112A/ru not_active Application Discontinuation
- 2013-10-11 MX MX2015004414A patent/MX2015004414A/es unknown
- 2013-10-11 SG SG11201502684YA patent/SG11201502684YA/en unknown
- 2013-10-11 BR BR112015008123A patent/BR112015008123A2/pt not_active IP Right Cessation
- 2013-10-11 KR KR1020157009188A patent/KR20150067189A/ko not_active Application Discontinuation
- 2013-10-11 PE PE2015000471A patent/PE20150638A1/es not_active Application Discontinuation
-
2015
- 2015-03-25 TN TNP2015000114A patent/TN2015000114A1/fr unknown
- 2015-03-29 IL IL238011A patent/IL238011A0/en unknown
- 2015-04-01 DO DO2015000078A patent/DOP2015000078A/es unknown
- 2015-04-08 CR CR20150184A patent/CR20150184A/es unknown
- 2015-04-08 CL CL2015000879A patent/CL2015000879A1/es unknown
- 2015-04-09 NI NI201500052A patent/NI201500052A/es unknown
- 2015-04-10 EC ECIEPI201514177A patent/ECSP15014177A/es unknown
- 2015-04-10 PH PH12015500795A patent/PH12015500795B1/en unknown
- 2015-05-11 ZA ZA2015/03246A patent/ZA201503246B/en unknown
- 2015-07-08 US US14/793,773 patent/US9415055B2/en not_active Expired - Fee Related
-
2016
- 2016-02-18 HK HK16101729.8A patent/HK1213880A1/zh unknown
- 2016-07-08 US US15/205,850 patent/US9593105B2/en not_active Expired - Fee Related
-
2017
- 2017-01-25 US US15/415,073 patent/US9861639B2/en not_active Expired - Fee Related
- 2017-02-27 PH PH12017500351A patent/PH12017500351A1/en unknown
- 2017-12-20 US US15/848,711 patent/US10124010B2/en not_active Expired - Fee Related
-
2018
- 2018-04-25 JP JP2018083786A patent/JP2018140995A/ja not_active Ceased
- 2018-10-10 US US16/156,648 patent/US20190307766A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001046200A1 (fr) * | 1999-12-22 | 2001-06-28 | Astrazeneca Ab | Nouveaux derives de piperidine et de piperazine |
WO2009132000A1 (fr) * | 2008-04-22 | 2009-10-29 | Janssen Pharmaceutica Nv | Antagonistes de p2x7 substitués par une quinoline ou isoquinoline |
Non-Patent Citations (16)
Title |
---|
"ACS Style Guide", 1997, article "The ACS Style guide - A manual for authors and editors" |
"Diagnostic and Statistical Manual of Mental Disorders", 2000, AMERICAN PSYCHIATRIC ASSOCIATION |
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO. |
CHESSEL ET AL., PAIN, vol. 114, 2005, pages 386 - 96 |
COSTE ET AL., TETRAHEDRON LETT., vol. 31, no. 2, 1990, pages 205 |
DIVIRGILIO ET AL., DRUG DEV RES, vol. 45, 1998, pages 207 - 13 |
FERRARI ET AL., NEUROPHARMACOL, vol. 36, 1997, pages 1295 - 301 |
J. JAQUES; A. COLLET; S. WILEN: "Enantiomers, Racemates, and Resolutions", 1981, JOHN WILEY AND SONS |
MONGIN; FLORENCE, TETRAHEDRON LETT., vol. 37, 1996, pages 6551 - 6554 |
MONIF ET AL., J NEUROSCI, vol. 29, 2009, pages 3781 - 91 |
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 2 |
SHAIKH; TANVEER MAHAMMAD ALI, J.ORG. CHEM, vol. 71, 2006, pages 5043 - 5046 |
SPERLAGH ET AL., PROGRESS IN NEUROBIOLOGY, vol. 7, 2006, pages 327 - 346 |
SURPRENANT ET AL., SCIENCE, vol. 272, 1996, pages 735 - 41 |
T. GREEN ET AL.: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
VIANNA ET AL., EPILEPSIA, vol. 43, 2002, pages 27 - 229 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2906549B1 (fr) | Dérivés de n-(2-(amine cyclique)ethyl)benzamide en tant qu'inhibiteurs de p2x7 | |
EP2906546B1 (fr) | Benzamides | |
EP2027107B1 (fr) | 2, 4 -diamino pyrimidine en tant qu'inhibiteurs de kinases du cycle cellulaire | |
AU2005316599A1 (en) | Pyrimidine inhibitors of ERK protein kinase and uses therof | |
EP3980410A1 (fr) | Dérivés de n-(4-(5-chloropyridin-3-yl)phényl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide et des composés apparentés servant d'inhibiteurs de ctps1 humains pour le traitement de maladies prolifératives | |
OA18987A (en) | N-(2-(cyclic amine) ethyl) benzamide derivatives as P2X7 inhibitors | |
OA17264A (en) | Benzamides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2906549 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200312 |